1. Pink Sheet
  2. >>Biosimilars & Generics
  3. >>Generics

Generic Companies Race To Withdraw ANDAs

 
• By Derrick Gingery

Industry consolidation may be a reason ANDA withdrawals have increased during GDUFA II.

Generics
After 606 ANDAs were removed in FY 2018, another 252 have been pulled in FY 2019, many of them approved applications. • Source: Shutterstock

Firms continue to withdraw ANDAs at high rates in fiscal year 2019, offering another look at the changing landscape of the generic industry.

Sponsors had pulled 252 original ANDAs through May, according to the most recent data from the US Food and Drug...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Generics

More from Biosimilars & Generics

Lupin Concedes To Harmony On Generic Wakix With 2030 Launch Agreement

 
• By Dean Rudge

Lupin became the latest ANDA sponsor to settle patent-infringement litigation over Harmony Biosciences’ Wakix (pitolisant hydrochloride), which has been touted as a potential blockbuster.

EU Decision Time For Madrigal’s MASH Drug Resmetirom And 11 Others

 
• By Eliza Slawther

Madrigal Pharmaceuticals’ resmetirom could become the first approved treatment for non-cirrhotic metabolic dysfunction-associated steatohepatitis in the EU, if the European Medicines Agency issues a positive opinion for the drug later this week.

US FDA Could Miss User Fee Spending Triggers With House FY 2026 Funding

 
• By Sarah Karlin-Smith and Derrick Gingery

FDA employees are concerned that while the budget authority total proposed for fiscal year 2026 meets the user fee appropriations' triggers, the FDA could have trouble meeting allocation triggers without cuts to non-review work.